ClinicalTrials.gg
RecruitingNCT07557602Updated Oct 26, 2026

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

A Phase 1 interventional study of VXCO-102 and Placebo in EBV, sponsored by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Prevention

Updated Oct 26, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Epstein-Barr Virus Infections with a site in Australia — 3 open to participants now, 5 under way, 2 of them phase 3. Epstein-Barr Virus Infections · Australia.

Started
2026
with 2 others
Phase 1
4 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company

Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, this one is one of 3 that started in 2026, is one of 4 in phase 1, and was the 10th registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

3 of the 10 studies in Epstein-Barr Virus Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epstein-Barr Virus Infections with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.

Read the detailed description

This first-in-human, dose-escalation Phase 1 trial evaluates the safety, tolerability, and immunogenicity of VXCO-102 in healthy young adults across multiple sites in Australia.

The trial will enroll up to 90 participants aged 18-25. After sentinel safety review in each dose cohort, participants will be randomized to receive VXCO-102 or placebo, with a booster at Week 8.

All participants will undergo ongoing safety monitoring and immune response assessments through clinical evaluations, sample collection, and participant reporting.

03

Conditions studied

  • EBV

Keywords

  • EBV
  • vaccine
  • mRNA
  • first in human
  • Epstein-Barr virus
04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 25 years, inclusive
  • Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment

Exclusion criteria

Exclusion Criteria:

  • Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
  • Likely or confirmed myocarditis or pericarditis
  • Prior receipt of an EBV vaccine
  • Prior receipt of a licensed vaccine within 56 days prior to Day 1
  • Received more than 10 days of any systemic or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
  • For participants of : pregnant, breastfeeding or planning to become pregnant during the study

Note: Other inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Group 1

    Dose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8

    Biological: VXCO-102

  • Experimental
    Group 2

    Dose 2 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8

    Biological: VXCO-102

  • Experimental
    Group 3

    Dose 3 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8

    Biological: VXCO-102

  • Placebo comparator
    Placebo

    Sodium Chloride administered IM by needle and syringe at Day 1 and Week 8

    Biological: Placebo

Interventions

  • BiologicalVXCO-102

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (BP grade)

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Reactions

    Time frame: 7 days after each product administration

  2. Number of Participants with Unsolicited Adverse Events

    Time frame: Up to 28 days after each product administration

  3. Number of Participants with Serious Adverse Events (SAEs) including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 to end of study (Day 357)

Secondary outcomes

  1. Rate and Magnitude of Neutralizing Antibody Responses

    Time frame: Day 1 and 85

07

Study locations

2 of 2 sites recruiting
  • Q-Pharm Pty Ltd/Nucleus Network Pty Ltd
    Herston, Queensland 4006, Australia
    Recruiting
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start May 2026 → Nov 2026, primary completion Aug 2027 → Feb 2028 and completion Aug 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
Nov 16, 2026was May 2026
Primary completionEst.
Feb 29, 2028was Aug 2027
CompletionEst.
Feb 29, 2028was Aug 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Q-Pharm Pty Ltd/Nucleus Network Pty Ltd · Herston, Australiano status→Recruiting
  • Nucleus Network Pty Ltd · Melbourne, Australiano status→Recruiting
Oct 26, 2026
Start date
May 4, 2026→Nov 16, 2026
Oct 26, 2026
Primary completion
Aug 31, 2027→Feb 29, 2028
Oct 26, 2026
Study completion
Aug 31, 2027→Feb 29, 2028
Oct 26, 2026
Enrollment
45→82
Oct 26, 2026
Interventions
Arm changed Group 4→Placebo
Oct 26, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedRate and Magnitude of neutralizing antibody responseNeutralizing Antibody ResponsesTime frame: Day 1 and 85
Oct 26, 2026
Sponsor
Vaccine Company, Inc.→Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Q-Pharm Pty Ltd/Nucleus Network Pty Ltd · Herston, Australiano status→Recruiting
    • Nucleus Network Pty Ltd · Melbourne, Australiano status→Recruiting
    Start date May 4, 2026→Nov 16, 2026
    Primary completion Aug 31, 2027→Feb 29, 2028
    Study completion Aug 31, 2027→Feb 29, 2028
    Enrollment 45→82
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedRate and Magnitude of neutralizing antibody responseNeutralizing Antibody ResponsesTime frame: Day 1 and 85
    Interventions Arm changed Group 4→Placebo
    Sponsor Vaccine Company, Inc.→Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
    + 4 other changes: identifiers, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07557602
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Christina Chang
Contact
melbourne@nucleusnetwork.com
(+61) 3 8593 9801

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion